Head-to-head comparison of multi-dose oritavancin and dalbavancin for complicated infections: A propensity score-matched analysis.

Autor: Steuber TD; University of Missouri-Kansas City School of Pharmacy, Columbia, MO. Electronic address: steubertd@umkc.edu., Gipson H; Department of Pharmacy, Huntsville Hospital, Huntsville, AL., Boyett B; Department of Pharmacy, Huntsville Hospital, Huntsville, AL., Belk M; Department of Pharmacy, Huntsville Hospital, Huntsville, AL., Thayer B; Department of Pharmacy, University Hospital, Columbia, MO., Edwards J; Department of Pharmacy, Huntsville Hospital, Huntsville, AL.
Jazyk: angličtina
Zdroj: International journal of antimicrobial agents [Int J Antimicrob Agents] 2024 Jun; Vol. 63 (6), pp. 107165. Date of Electronic Publication: 2024 Apr 01.
DOI: 10.1016/j.ijantimicag.2024.107165
Abstrakt: Background: Oritavancin and dalbavancin are long-acting lipoglycopeptide antibiotics approved for the treatment of skin and skin structure infections. Recently, they have been used for outpatient antimicrobial therapy for complicated infections. No head-to-head studies exist for this purpose.
Objective: To compare outcomes of patients treated with multiple doses of oritavancin or dalbavancin for complicated infections.
Patients and Methods: This was a single-centre, retrospective cohort study evaluating adult patients who received two or more doses of lipoglycopeptides for complicated infections from February 2019 through December 2022. Patients receiving oritavancin were compared to dalbavancin after propensity score-matching. The primary endpoint was clinical success at 90 days. Other endpoints included: 30-day re-admission, 30-day mortality, adverse drug reactions (ADRs), and changes in white blood cell count and inflammatory markers after the first dose.
Results: After exclusions and propensity score-matching, 131 matched pairs (N = 262) were included in the analysis. Most patients were receiving lipoglycopeptide therapy for osteomyelitis. There was no significant difference in clinical success at 90 days in patients who received oritavancin compared to those who received dalbavancin (99 [76%] vs. 103 [79%], respectively; P = 0.556). There was no significant difference in secondary endpoints, however, there was a trend towards higher incidence of ADRs oritavancin compared to dalbavancin (9 [7%] vs. 2 [2%], respectively; P = 0.060) which led to more treatment discontinuation.
Conclusion: There was no significant difference in efficacy between multi-dose oritavancin and dalbavancin for the treatment of complicated infections. Both agents were generally well tolerated; however, dalbavancin may be better tolerated when long-term treatment is warranted.
(Copyright © 2024 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: